Intra-Cellular Therapies – Amendment No. 1 to Employment Agreement (November 9th, 2016)
This Amendment No. 1 to Employment Agreement (the Amendment), dated as of November 9, 2016, is entered into by and between Intra-Cellular Therapies, Inc. (the Company), and Robert Davis (the Executive), for purposes of amending the terms of that certain Employment Agreement dated November 4, 2015 (the Agreement).
November 1, 2005 (November 3rd, 2005)
This separation agreement (the Agreement) sets forth the terms of the agreement between ACADIA Pharmaceuticals Inc. (the Company) and you.
Consultant Agreement (November 3rd, 2005)
THIS AGREEMENT, effective November 4, 2005 (the Effective Date), by and between ROBERT E. DAVIS, PH.D., an individual (hereinafter CONSULTANT), and ACADIA PHARMACEUTICALS INC., a Delaware corporation with a place of business at 3911 Sorrento Valley Boulevard, San Diego, California 92121 (hereinafter ACADIA).
ACADIA Pharmaceuticals Inc. Description of Executive Officer Annual Incentive Cash Compensation Program (March 18th, 2005)
The Compensation Committee (the Committee) of the Board of Directors (the Board) of ACADIA Pharmaceuticals Inc. (the Company) has recommended to the Board, and the Board has approved, incentive cash compensation for the Companys executive officers pursuant to an annual incentive cash compensation program. The program provides for an annual incentive cash compensation target equal to a percentage of each executives base salaries as follows: 30% for Uli Hacksell, CEO; 26.5% for Mark R. Brann, President and CSO; 23.5% for Thomas H. Aasen, Vice President and CFO, Robert E. Davis, Executive Vice President, Drug Discovery and Development, and Brian Lundstrom, Senior Vice President, Business Development; and 20% for Bo-Ragnar Tolf, Vice President, Chemistry.